

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

ANTI-TUMOR NANODRUG “SYHA1908 FOR INJECTION” OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Class 1 new drug “SYHA1908 for Injection” (the “**Product**”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Company, has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

SYHA1908 (the compound) is a new-generation taxane with high efficacy and low toxicity acting on the microtubule or tubulin system. Utilising human albumin as the carrier, the Product is independently developed by the Group to achieve effective delivery of the new-generation taxane in the body.

The compound has no cytotoxicity towards normal tissue, but it can be converted into active substance by enzymes in the tumor microenvironment to activate anti-tumor effect, thus having a significantly improved safety window. When compared with taxanes available on the market, its safety is increased by at least >100 times; while its efficacy is comparable. Therefore, the compound can improve the clinical limitation of the inability to administer taxane drugs at higher dose due to dose-limiting toxicity.

The clinical indication of this approval is for the treatment of solid tumors. The preclinical study demonstrated that the Product has good anti-tumor activity in several models of solid tumors, providing a promising prospect of demonstrating good anti-tumor efficacy in clinical trials.

The Product is a Class 1 chemical drug under the registration system in China and currently there is no product of the same type available in the global market. The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 7 February 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Professor WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.